Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor

Authors:
  • VCVincent S. Chan
    Vincent S. Chan
  • ACAlan Christesen
    Alan Christesen
  • TGTimothy Grieme
    Timothy Grieme
  • MMMathew Mulhern
    Mathew Mulhern
  • YPYu-Ming Pu
    Yu-Ming Pu
  • MWMichael D. Wendt
    Michael D. Wendt

Abstract
The process development of a new synthetic route leading to an efficient and robust synthetic process for Venetoclax (1: the active pharmaceutical ingredient (API) in Venclexta™) is described. The redesigned synthesis features a Buchwald-Hartwig amination to construct the core ester 23c in a convergent fashion by connecting two key building blocks (4c and 26), which is then followed by a uniquely effective saponification reaction of 23c using anhydrous hydroxide generated in-situ to obtain 2. Finally, the coupling of the penultimate core acid 2 with sulfonamide 3 furnishes drug substance 1 with consistently high quality. The challenges and solutions for the key Pd-catalyzed C-N cross-coupling will also be discussed in detail. The improved synthesis overcomes many of the initial scale-up challenges and was accomplished in 46% overall yield from 3,3-dimethyldicyclohexanone 6, more than doubling the overall yield of the first generation route. The new process was successfully implemented for producing large quantities of 1 with >99% area purity.
Funding Information
  • AbbVie